Specific Cognitive–Psychopathological Phenotypes in Patients With Early Stages of Subcortical Vascular Neurocognitive Disorders: A Hospital-Based Case–Control Study
Restricted accessResearch articleFirst published online September, 2018
Specific Cognitive–Psychopathological Phenotypes in Patients With Early Stages of Subcortical Vascular Neurocognitive Disorders: A Hospital-Based Case–Control Study
Diagnosis of subcortical vascular neurocognitive disorders’ (ScVNCDs) is currently based on neuropsychological and neuroimaging approaches; nevertheless, clinical features, apart from cognitive impairments (CI), may provide additional information about ScVNCD phenotypes. We aimed to determine whether CI and neuropsychiatric symptoms (NPS) form such clinical phenotypes in the mild and early stage of major ScVNCD.
Methods:
Our sample included 88 cognitively normal elderly individuals, 100 patients with mild ScVNCD, and 60 patients with early major ScVNCD. All participants had neuropsychological, neuropsychiatric, neurological, and functional evaluations. The prevalence of NPS was based on the neuropsychiatric inventory. The statistical analyses included parametric and nonparametric tests and multivariate regression.
Results:
The severity of executive dysfunction increased through stages of ScVNCD progression (P < .0001). The NPS with significant predictive value for mild ScVNCD membership was depression (odds ratio [OR] = 7.4), whereas for early major ScVNCD were depression (OR = 5.5) and apathy (OR = 7.6). Those distinguishing NPS and impairments of executive tests’ performance significantly correlated (P < .05) in patients with mild/major ScVNCD.
Conclusion:
Significant correlation between pathognomonic cognitive and NPS in compared groups suggest that dysexecutive-depressive syndrome can be the main phenotype in mild ScVNCD, while dysexecutive-depressive-apathetic syndrome in the early stage of major ScVNCD. Obtained cognitive–psychopathological phenotypes may allow a better comprehension of the ScVNCD pathophysiology and improve the diagnostic and therapeutic approach.
American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. DSM-5. Washington, DC: American Psychiatric Publishing; 2013.
2.
GoodmanRALochnerKAThambisettyMWingoTSPosnerSFLingSM. Prevalence of dementia subtypes in United States Medicare fee-for-service beneficiaries, 2011–2013. Alzheimers Dement. 2017;13(1):28–37.
3.
SmithEE. Clinical presentations and epidemiology of vascular dementia. Clin Sci (Lond). 2017;131(11):1059–1068.
4.
OharaTHataJYoshidaD. Trends in dementia prevalence, incidence, and survival rate in a Japanese community. Neurology. 2017;88(20):1925–1932.
JokinenHKalskaHYlikoskiR. Longitudinal cognitive decline in subcortical ischemic vascular disease – the LADIS study. Cerebrovasc Dis. 2009;27(4):384–391.
7.
ErkinjunttiTInzitariDPantoniL. Research criteria for subcortical vascular dementia in clinical trials. J Neural Transm Suppl. 2000;59:23–30.
8.
WuYTFratiglioniLMatthewsFE. Dementia in Western Europe: epidemiological evidence and implications for policy making. Lancet Neurol. 2016;15(1):116–124.
9.
FrisoniGBGalluzziSBrescianiLZanettiOGeroldiC. Mild cognitive impairment with subcortical vascular features: clinical characteristics and outcome. J Neurol. 2002;249(10):1423–1432.
10.
AnorCJO’ConnorSSaundATang-WaiDFKerenRTartagliaMC. Neuropsychiatric symptoms in Alzheimer disease, vascular dementia, and mixed dementia. Neurodegener Dis. 2017;17(4-5):127–134.
11.
OkuraTPlassmanBLSteffensDCLlewellynDJPotterGGLangaKM. Prevalence of neuropsychiatric symptoms and their association with functional limitations in older adults in the United States: the Aging, Demographics, and Memory study. J Am Geriatr Soc. 2010;58(2):330–337.
12.
StellaFRadanovicMBalthazarMLCanineuPRde SouzaLCForlenzaOV. Neuropsychiatric symptoms in the prodromal stages of dementia. Curr Opin Psychiatry. 2014;27(3):230–235.
13.
TielCSudoFCAlvesGS. Neuropsychiatric symptoms in vascular cognitive impairment: a systematic review. Dement Neuropsychol. 2015;9(3):230–236.
14.
TuMCHuangWHHsuYHLoCPDengJFHuangCF. Comparison of neuropsychiatric symptoms and diffusion tensor imaging correlates among patients with subcortical ischemic vascular disease and Alzheimer’s disease. BMC Neurol. 2017;17(1):144. doi:10.1186/s12883-017-0911-5.
15.
LevadaOACherednichenkoNVTroyanAS. Neuropsychiatric symptoms in patients with the main etiological types of mild neurocognitive disorders: a hospital-based case–control study. Front Psychiatry. 2017;8:75. doi:10.3389/fpsyt.2017.00075.
16.
MorrisJC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993;43(11):2412–2414.
17.
FolsteinMFFolsteinSEMcHughPR. “Mini-Mental State”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198.
18.
HamrickIHafizRCummingsDM. Use of days of the week in a modified Mini-Mental State Exam (M-MMSE) for detecting geriatric cognitive impairment. J Am Board Fam Med. 2013;26(4):429–435.
19.
KasaiMMeguroMNakamuraKNakatsukaMOuchiYTanakaN. Screening for very mild subcortical vascular dementia patients aged 75 and above using the Montreal Cognitive Assessment and Mini-Mental State Examination in a community: the Kurihara project. Dement Geriatr Cogn Dis Extra. 2012;2(1):503–515.
20.
LuriaAR. Higher Cortical Functions in Man. New York, NY: Basic Books; 1966.
21.
SchoenbergMRScottJG. The Little Black Book of Neuropsychology. New York, NY: Springer Science+Business Media, LLC; 2011.
22.
LibonDJSwensonRABarnoskiEJSandsLP. Clock drawing as an assessment tool for dementia. Arch of Clin Neuropsychol. 1993;8(5):405–415.
23.
BorkowskiJGBentonALSpreenO. Word fluency and brain damage. Neuropsychologia. 1967;5:135–140.
24.
CummingsJLMegaMGrayKRosenberg-ThompsonSCarusiDAGornbeinJ. The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308–2314.
25.
SchneiderLSTariotPNLyketsosCG. National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer Disease Trial methodology. Am J Geriatr Psychiatry. 2001;9(4):346–360.
26.
TinettiME. Performance-oriented assessment of mobility problems in elderly patients. J Am Geriatr Soc. 1986;34(2):119–126.
27.
BucksRSAshworthDLWilcockGKSiegfriedK. Assessment of activities of daily living in dementia: development of the Bristol Activities of Daily Living Scale. Age Ageing. 1996;25(2):113–120.
28.
Department of Economic and Social Affairs/Population Division. World Population Ageing 2009. New York: ONU; 2009.
29.
GuptaMDasguptaAKhwajaGAChowdhuryDPatidarYBatraA. The profile of behavioral and psychological symptoms in vascular cognitive impairment with and without dementia. Ann Indian Acad Neurol. 2013;16(4):599–602.
30.
ChinJSeoSWKimSH. Neurobehavioral dysfunction in patients with subcortical vascular mild cognitive impairment and subcortical vascular dementia. Clin Neuropsychol. 2012;26(2):224–238.
31.
KimHJKangSJKimC. The effects of small vessel disease and amyloid burden on neuropsychiatric symptoms: a study among patients with subcortical vascular cognitive impairments. Neurobiol Aging. 2013;34(7):1913–1920.
32.
AloscoMLSpitznagelMBCohenR. Reduced cerebral perfusion predicts greater depressive symptoms and cognitive dysfunction at a 1-year follow-up in patients with heart failure. Int J Ger Psychiatry. 2014;29(4):428–436.
33.
LiuQZhuZTeipelSJ. White matter damage in the cholinergic system contributes to cognitive impairment in subcortical vascular cognitive impairment, no dementia. Front Aging Neurosci. 2017;9:47. doi:10.3389/fnagi.2017.00047.
34.
TaylorWDAizensteinHJAlexopoulosGS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry. 2013;18(9):963–974.
35.
RajkowskaGMiguel-HidalgoJJDubeyPStockmeierCAKrishnanKR. Prominent reduction in pyramidal neurons density in the orbitofrontal cortex of elderly depressed patients. Biol Psychiatry. 2005;58(4):297–306.
36.
GunningFMChengJMurphyCF. Anterior cingulate cortical volumes and treatment remission of geriatric depression. Int J Geriatr Psychiatry. 2009;24(8):829–836.
37.
ShelineYIPieperCFBarchDM. Support for the vascular depression hypothesis in late-life depression: results of a 2-site, prospective, antidepressant treatment trial. Arch Gen Psychiatry. 2010;67(3):277–285.
38.
van ReekumRStussDTOstranderL. Apathy: why care?J Neuropsychiatry Clin Neurosci. 2005;17(1):7–19.
39.
TullbergMFletcherEDeCarliC. White matter lesions impair frontal lobe function regardless of their location. Neurology. 2004;63(2):246–253.
40.
LevyRDuboisD. Apathy and the functional anatomy of the prefrontal cortex-basal ganglia circuits. Cereb Cortex. 2006;16(7):916–928.
